Literature DB >> 23883383

Riociguat for pulmonary hypertension--a glass half full.

Stephen L Archer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23883383     DOI： 10.1056/NEJMe1306684

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Authors:  Diana Khaybullina; Ami Patel; Tina Zerilli
Journal:  P T       Date:  2014-11

Review 2.  The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure.

Authors:  John J Ryan; Stephen L Archer
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 3.  Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension.

Authors:  Andrea L Frump; Sébastien Bonnet; Vinicio A de Jesus Perez; Tim Lahm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-02       Impact factor: 5.464

Review 4.  Pharmacotherapy for pulmonary arterial hypertension.

Authors:  Vishal Parikh; Anju Bhardwaj; Ajith Nair
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

Review 5.  Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2014-11       Impact factor: 9.546

Review 6.  Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Authors:  A Dasgupta; L Bowman; C L D'Arsigny; S L Archer
Journal:  Clin Pharmacol Ther       Date:  2014-11-28       Impact factor: 6.875

7.  Riociguat: first global approval.

Authors:  Daniel Conole; Lesley J Scott
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 8.  Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat.

Authors:  Zachary R Smith; Charles T Makowski; Rana L Awdish
Journal:  Ther Clin Risk Manag       Date:  2016-06-10       Impact factor: 2.423
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.